VIM and breast cancer: Accordingly, treatment with low-dose (10–20 μg/mL) EtOAc extracts for 24 h decreased cell migration by downregulating protein expression of MMP2, MMP9, cyclin B, vimentin, and snail protein in MDA-MB-231 cells, indicating decreased breast cancer cell growth both in vivo and in vitro.